The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats

Pain

Volumn 154, Issue 5, 2013, Pages 700-707

  Hirsch, Silke ^a   Corradini, Laura ^a   Just, Stefan ^a   Arndt, Kirsten ^a   Doods, Henri ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Animals; Behaviour; Calcitonin gene related peptide; Electrophysiology; Inflammatory pain; Spinal cord

Indexed keywords

FREUND ADJUVANT; IODOACETIC ACID; OLCEGEPANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN ELECTROPHYSIOLOGY; CELL ACTIVITY; CONTROLLED STUDY; HYPERSENSITIVITY; IN VIVO STUDY; INFLAMMATORY PAIN; LUMBAR SPINAL CORD; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD DORSAL HORN; WEIGHT BEARING;

EID: 84878013858     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.01.002     Document Type: Article

References (74)

1. Adwanikar H, Ji G, Li W, Doods H, Willis WD, Neugebauer V. Spinal CGRP1 receptors contribute to supraspinally organized pain behavior and pain-related sensitization of amygdala neurons. PAIN 2007;132:53-66.
2. Antunez C, Torres MJ, Lopez S, Rodriguez-Pena R, Blanca M, Mayorga C, Santamaria-Babi LF. Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis. Br J Dermatol 2009;161:547-53.
3. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004;500:315-30.
4. Bernardi A, Zilberstein AC, Jager E, Campos MM, Morrone FB, Calixto JB, Pohlmannz AR , Guterres SS, Battastini AM. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol 2009;158:1104-11.
5. Bird GC, Han JS, Fu Y, Adwanikar H, Willis WD, Neugebauer V. Pain-related synaptic plasticity in spinal dorsal horn neurons: role of CGRP. Mol Pain 2006;2:31-43.
6. Boyce-Rustay JM, Zhong C, Kohnken R, Baker SJ, Simler GH, Wensink EJ, Decker MW, Honore P. Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. Neuropharmacology 2010;58:537-43.
7. Cottrell GS, Roosterman D, Marvizon JC, Song B, Wick E, Pikios S, Wong H, Berthelier C, Tang Y, Sternini C, Bunnett NW, Grady EF. Localization of calcitonin receptor-like receptor and receptor activity modifying protein 1 in enteric neurons, dorsal root ganglia, and the spinal cord of the rat. J Comp Neurol 2005;490:239-55.
8. Dodick DW, Kost J, Assaid C, Lines C, Ho TW. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia 2011;31:296-300.
9. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs 2001;2:1261-8.
10. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007;28:580-7.
11. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420-3.
12. Duraku LS, Hossaini M, Hoendervangers S, Falke LL, Kambiz S, Mudera VC, Holstege JC, Walbeehm ET, Ruigrok TJ. Spatiotemporal dynamics of reinnervation and hyperinnervation patterns by uninjured CGRP fibers in the rat foot sole epidermis after nerve injury. Mol Pain 2012;8:61.
13. Edvinsson L. Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev 2005;11:69-76.
14. Eisenach JC, Curry R, Hood DD, Yaksh TL. Phase I safety assessment of intrathecal ketorolac. PAIN 2002;99:599-604.
15. Eisenach JC, Curry R, Rauck R, Pan P, Yaksh TL. Role of spinal cyclooxygenase in human postoperative and chronic pain. Anesthesiology 2010;112:1225-33.
16. Eisenach JC, Curry R, Tong C, Houle TT, Yaksh TL. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology 2010;112:1216-24.
17. El-Setouhy DA, El-Ashmony SM. Ketorolac trometamol topical formulations: release behaviour, physical characterization, skin permeation, efficacy and gastric safety. J Pharm Pharmacol 2010;62:25-34.
18. Farinelli I, De FS, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med 2009;4:367-73.
19. Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005;25:5877-83.
20. Geisslinger G, Schaible HG. New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers. J Clin Pharmacol 1996;36:513-20.
21. Gu XL, Yu LC. The colocalization of CGRP receptor and AMPA receptor in the spinal dorsal horn neuron of rat: a morphological and electrophysiological study. Neurosci Lett 2007;414:237-41.
22. Hall SR, Milne B, Loomis C. Spinal action of ketorolac, S(+)-and R(-)-ibuprofen on non-noxious activation of the catechol oxidation in the rat locus coeruleus: evidence for a central role of prostaglandins in the strychnine model of allodynia. Anesthesiology 1999;90:165-73.
23. Han JS, Adwanikar H, Li Z, Ji G, Neugebauer V. Facilitation of synaptic transmission and pain responses by CGRP in the amygdala of normal rats. Mol Pain 2010;6:10.
24. Han JS, Li W, Neugebauer V. Critical role of calcitonin gene-related peptide 1 receptors in the amygdala in synaptic plasticity and pain behavior. J Neurosci 2005;25:10717-28.
25. Hay DL, Howitt SG, Conner AC, Doods H, Schindler M, Poyner DR. A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br J Pharmacol 2002;137:80-6.
26. Hay DL, Poyner D. The preclinical pharmacology of BIBN4096BS, a CGRP antagonist. Cardiovasc Drug Rev 2005;23:31-42.
27. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, Li Q, Yang H, Luo J, Li ZY, Wang Q, Lu YJ, Bao L, Zhang X. Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron 2011;69:120-31.
28. Hershey JC, Corcoran HA, Baskin EP, Salvatore CA, Mosser S, Williams TM, Koblan KS, Hargreaves RJ, Kane SA. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 2005;127:71-7.
29. Hou JF, Yu LC. Blockade effects of BIBN4096BS on CGRP-induced inhibition on whole-cell K+ currents in spinal dorsal horn neuron of rats. Neurosci Lett 2010;469:15-8.
30. Hu B, Doods H, Treede RD, Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. PAIN 2009;143:206-12.
31. Huang D, Li SY, Dhaka A, Story GM, Cao YQ. Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura. Mol Pain 2012;8:66.
32. Huang J, Stohl LL, Zhou X, Ding W, Granstein RD. Calcitonin gene-related peptide inhibits chemokine production by human dermal microvascular endothelial cells. Brain Behav Immun 2011;25:787-99.
33. Inagaki S, Kito S, Kubota Y, Girgis S, Hillyard CJ, MacIntyre I. Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res 1986;374:287-98.
34. Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645-56.
35. Just S, Arndt K, Doods H. The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes. Neurosci Lett 2005;381:120-4.
36. Kilo S, Harding-Rose C, Hargreaves KM, Flores CM. Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin. PAIN 1997;73:201-7.
37. Kim BY, Doh HJ, Le TN, Cho WJ, Yong CS, Choi HG, Kim JS, Lee CH, Kim DD. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies. Int J Pharm 2005;293:193-202.
38. Koulchitsky S, Fischer MJ, Messlinger K. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 2009;29:408-17.
39. Kroeger I, Erhardt A, Abt D, Fischer M, Biburger M, Rau T, Neuhuber WL, Tiegs G. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. J Hepatol 2009;51:342-53.
40. Kruger L, Mantyh PW, Sternini C, Brecha NC, Mantyh CR. Calcitonin gene-related peptide (CGRP) in the rat central nervous system: patterns of immunoreactivity and receptor binding sites. Brain Res 1988;463:223-44.
41. Kumar K, Polston GR, Wallace MS. The effect of intravenous ketorolac on capsaicin-induced deep tissue hyperalgesia. Anesth Analg 2006;103:696-702.
42. Lee CY, Perez FM, Wang W, Guan X, Zhao X, Fisher JL, Guan Y, Sweitzer SM, Raja SN, Tao YX. Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury. Eur J Pain 2011;15:669-75.
43. Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K. Calcitonin receptor-like receptor (CLR), receptor activitymodifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008;507:1277-99.
44. Lim YY, Kim HM, Lee HI, Mun SK, Kim CW, Kim MN, Kim BJ. A comparison of neuropeptide expression in skin with allergic contact dermatitis in human and mouse. Int J Dermatol 2012;51:939-46.
45. Ling QD, Chien CC, Wen YR, Fu WM, Sun WZ. The pattern and distribution of calcitonin gene-related peptide (CGRP) terminals in the rat dorsal following neonatal peripheral inflammation. Neuroreport 2003;14:1919-21.
46. Little JW, Chen Z, Doyle T, Porreca F, Ghaffari M, Bryant L, Neumann WL, Salvemini D. Supraspinal peroxynitrite modulates pain signaling by suppressing the endogenous opioid pathway. J Neurosci 2012;32:10797-808.
47. Ma W. Chronic prostaglandin E2 treatment induces the synthesis of the painrelated peptide substance P and calcitonin gene-related peptide in cultured sensory ganglion explants. J Neurochem 2010;115:363-72.
48. Massaad CA, Safieh-Garabedian B, Poole S, Atweh SF, Jabbur SJ, Saade NE. Involvement of substance P, CGRP and histamine in the hyperalgesia and cytokine upregulation induced by intraplantar injection of capsaicin in rats. J Neuroimmunol 2004;153:171-82.
49. Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache 2012;52:1411-27.
50. Mogil JS, Miermeister F, Seifert F, Strasburg K, Zimmermann K, Reinold H, Austin JS, Bernardini N, Chesler EJ, Hofmann HA, Hordo C, Messlinger K, Nemmani KV, Rankin AL, Ritchie J, Siegling A, Smith SB, Sotocinal S, Vater A, Lehto SG, Klussmann S, Quirion R, Michaelis M, Devor M, Reeh PW. Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci U S A 2005;102:12938-43.
51. Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol 2011;13:1-14.
52. Mousa SA, Shaqura M, Brendl U, Al-Khrasani M, Furst S, Schafer M. Involvement of the peripheral sensory and sympathetic nervous system in the vascular endothelial expression of ICAM-1 and the recruitment of opioidcontaining immune cells to inhibit inflammatory pain. Brain Behav Immun 2010;24:1310-23.
53. Nader ND, Li CM, Dosluoglu HH, Ignatowski TA, Spengler RN. Adjuvant therapy with intrathecal clonidine improves postoperative pain in patients undergoing coronary artery bypass graft. Clin J Pain 2009;25:101-6.
54. Neugebauer V, Li W. Differential sensitization of amygdala neurons to afferent inputs in a model of arthritic pain. J Neurophysiol 2003;89:716-27.
55. Neugebauer V, Li W, Bird GC, Bhave G, Gereau RW. Synaptic plasticity in the amygdala in a model of arthritic pain: differential roles of metabotropic glutamate receptors 1 and 5. J Neurosci 2003;23:52-63.
56. Pi LQ, Jin XH, Hwang ST , Lee WS. Effects of calcitonin gene-related peptide on the immune privilege of human hair follicles. Neuropeptide 2013;47:51-7.
57. Recober A, Russo AF. Calcitonin gene-related peptide: an update on the biology. Curr Opin Neurol 2009;22:241-6.
58. Roeska K, Doods H, Arndt K, Treede RD, Ceci A. Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. PAIN 2008;139:349-57.
59. Rudolf K, Eberlein W, Engel W, Pieper H, Entzeroth M, Hallermayer G, Doods H. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidi nyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 2005;48: 5921-31.
60. Schattauer SS, Miyatake M, Shankar H, Zietz C, Levin JR, Liu-Chen LY, Gurevich VV, Rieder MJ, Chavkin C. Ligand directed signaling differences between rodent and human kappa opioid receptors. J Biol Chem 2012;287:41595-607.
61. Schindler M, Doods HN. Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [(3)H]BIBN4096BS. Eur J Pharmacol 2002;442:187-93.
62. Seifert H, Chesnut J, De SE, Rivier J, Vale W. Binding sites for calcitonin gene-related peptide in distinct areas of rat brain. Brain Res 1985;346:195-8.
63. Seybold VS, Galeazzaz MT , Garry MG, Hargreaves KM. Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Can J Physiol Pharmacol 1995;73:1007-14.
64. Sun RQ, Lawandz NB , Willis WD. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. PAIN 2003;104:201-8.
65. Troconiz IF, Wolters JM, Schaefer HG, Roth W. Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. Eur J Pharm Sci 2004;22:287-95.
66. Troltzsch M, Denekas T, Messlinger K. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 2007;562:103-10.
67. Tschopp FA, Henke H, Petermann JB, Tobler PH, Janzer R, Hokfelt T, Lundberg JM, Cuello C, Fischer JA. Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci U S A 1985;82:248-52.
68. Unlu N, Kocaoglan H, Sayin F, Hazirolan D, Demircan S, Basci N, Acar MA, Demir NM, Duman S. Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial. Can J Ophthalmol 2010;45:610-5.
69. Wang D, Gao Y, Ji H, Hong Y. Topical and systemic administrations of ketanserin attenuate hypersensitivity and expression of CGRP in rats with spinal nerve ligation. Eur J Pharmacol 2010;627:124-30.
70. WuD, Doods H, Arndt K, Schindler M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem Soc Trans 2002;30:468-73.
71. Yaksh TL, Dirig DM, Malmberg AB. Mechanism of action of nonsteroidal antiinflammatory drugs. Cancer Invest 1998;16:509-27.
72. Yaksh TL, Horais KA, Tozier N, Rathbun M, Richter P, Rossi S, Grafe M, Tong C, Meschter C, Cline JM, Eisenach J. Intrathecal ketorolac in dogs and rats. Toxicol Sci 2004;80:322-34.
73. Ye Z, Wimalawansa SJ, Westlund KN. Receptor for calcitonin gene-related peptide: localization in the dorsal and ventral spinal cord. Neuroscience 1999;92:1389-97.
74. Van Rossum D, Hanisch UK , Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997;21:649-78.